Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James R Blinn

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
EXS|March 5, 2003
Structure-based design of combinatorial librariesJohn H van Drie, Douglas C Rohrer, James R Blinn, et al.
Hypertension (Dallas, Tex. : 1979)|February 6, 2008
A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activityJessica D Dietz, Sarah Du, Charles W Bolten, et al.
Molecular Cell|May 15, 2007
The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondriaKaren L Leach, Steven M Swaney, Jerry R Colca, et al.
Journal of Medicinal Chemistry|April 23, 2010
Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridinesGraciela B Arhancet, Scott S Woodard, Jessica D Dietz, et al.
Journal of Medicinal Chemistry|August 3, 2010
Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonistsGraciela B Arhancet, Scott S Woodard, Kaliappan Iyanar, et al.
Journal of Medicinal Chemistry|August 3, 2010
Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathyMarvin J Meyers, Graciela B Arhancet, Susan L Hockerman, et al.
Journal of Medicinal Chemistry|August 22, 2018
Discovery of 3-Cyano- N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1 H-pyrrolo[2,3- b]pyridin-5-yl)benzamide: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse AgonistMark E Schnute, Mattias Wennerstål, Jennifer Alley, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
EXS|March 5, 2003
Structure-based design of combinatorial librariesJohn H van Drie, Douglas C Rohrer, James R Blinn, et al.
Hypertension (Dallas, Tex. : 1979)|February 6, 2008
A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activityJessica D Dietz, Sarah Du, Charles W Bolten, et al.
Molecular Cell|May 15, 2007
The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondriaKaren L Leach, Steven M Swaney, Jerry R Colca, et al.
Journal of Medicinal Chemistry|April 23, 2010
Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridinesGraciela B Arhancet, Scott S Woodard, Jessica D Dietz, et al.
Journal of Medicinal Chemistry|August 3, 2010
Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonistsGraciela B Arhancet, Scott S Woodard, Kaliappan Iyanar, et al.
Journal of Medicinal Chemistry|August 3, 2010
Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathyMarvin J Meyers, Graciela B Arhancet, Susan L Hockerman, et al.
Journal of Medicinal Chemistry|August 22, 2018
Discovery of 3-Cyano- N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1 H-pyrrolo[2,3- b]pyridin-5-yl)benzamide: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse AgonistMark E Schnute, Mattias Wennerstål, Jennifer Alley, et al.
Pageof 1